Skip to main content

Advertisement

Table 5 Review of literature since 2000: WAI and/or chemotherapy in patients with advanced endometrial cancer

From: Consolidation whole abdomen irradiation following adjuvant carboplatin-paclitaxel based chemotherapy for advanced uterine epithelial cancer: feasibility, toxicity and outcomes

Authors (year) No. patients Treatment Design Outcomes Comments Median follow-up
Smith RS [6] 48 WAI only retrospective 60% 3-y FS (79% for EAC and 47% for PS/CC) EAC: stage III-IV 37 mo.
77% 3-y OS (89% for EAC and 68% PS/CC) PS/CC: stage I-IV
Stewart KD [7] 119 WAI only prospective Stage III 5-y OS: 67% for EAC and 40% for SP/CC Stage III n = 81 (68%) 5.8 y
Stage III 5-y DFS: 62% for EAC and 34% for SP/CC
Dusenbery KE [9] 86 WAI only retrospective 55% 5-y PFS, 46% 10-y PFS, 38% 20-y PFS Concurrent cisplatin in 13/86 10 y
57% 5-y OS, 48% 10-y OS, 41% 20-y OS
Sutton G [8] 34 WAI only prospective 38% 5-y PFS for PS Stage I/II PS and CC only unknown
54% 5-y PFS for CC
Randall ME [5] 422 Chemo vs. WAI prospective 5-y PFS: 50% for chemo and 38% for WAI Adjusted for stage 74 mo.
5-y OS: 55% for chemo and 42% for WAI
Alvarez Secord A [11] 356 Chemo vs. RT vs. multi-modality retrospective 3-y PFS: 19% (chemo), 59% (RT), 62% (MM) 39% of WAI in RT group 38 mo.
3-y OS: 33% (chemo), 70% (RT), 79% (MM)
Fowler JM [20] 31 Multi-modality: chemo + WAI prospective 53% 5-y PFS Chemo 3 × AC 21 mo.
60% 5-y OS
Rochet N (present study) 20 Multi-modality: chemo + WAI retrospective 63% 1-y, 57% 2- and 3-y RFS TP based chemo 31.2 mo.
83% 1-y, 70% 2-y, 62% 3-y, 53% 4-and 5-y OS
Secord A [14] 109 Multi-modality: “sandwich” CRC vs. RC vs. CR retrospective 3-y PFS: 69% (CRC), 47% (RC), 52% (CR) various chemo (79% TP) 2.8 y
3-y OS: 88% (CRC), 54% (RC), 57% (CR)
WAI in 13%
Bruzzone M [12] 45 Multi-modality: chemo + pelvic RT retrospective 30% 9-yPFS 4 × PAC 63 mo.
53% 9-y OS No WAI
Geller MA [13] 42 Multi-modality: “sandwich” chemo + pelvic +/− EFRT prospective 87% 1-y PFS, 71% 3-y PFS, 64% 5-y PFS 6 × TP 28 mo.
No WAI
     95% 1-y OS, 90% 3-y OS, 71% 5-y OS   
  1. Abbreviations: No. Number of, WAI Whole abdomen radiotherapy, Chemo Chemotherapy, EFRT Extended-fields radiotherapy, EAC Endometrioid adenocarcinoma, PS Papillary serous, CC Clear cell, DFS Disease-free survival, PFS Progression-free survival, OS Overall survival, RFS Recurrence-free survival, MM Multi-modality, CRC Chemotherapy, interval radiotherapy, subsequent chemotherapy, RC Radiotherapy followed by chemotherapy, CR Chemotherapy followed by radiotherapy, RT Radiotherapy, TP Carboplatin/paclitaxel, PAC Cisplatin/doxorubicin/cytoxan, AC Doxorubicin/cisplatin.